Last reviewed · How we verify

Symptomatic relief of acute alcohol withdrawal — Treatment Landscape & Competitive Intelligence

Symptomatic relief of acute alcohol withdrawal (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Symptomatic relief of acute alcohol withdrawal, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Diazepam 2Mg encapsulated Tab Diazepam 2Mg encapsulated Tab The University of Hong Kong Benzodiazepine GABA-A receptor (allosteric modulator)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. The University of Hong Kong · 1 drug in Symptomatic relief of acute alcohol withdrawal

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Symptomatic relief of acute alcohol withdrawal:

Cite this brief

Drug Landscape (2026). Symptomatic relief of acute alcohol withdrawal — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/symptomatic-relief-of-acute-alcohol-withdrawal. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing